400 billion market fight!

According to statistics, in 2019 the global market size of peptide drugs 281.
5 Yi US dollars, is expected in 2027 will reach 667.
6 Yi US dollars (about 429.
6 billion yuan)
.

Peptide drug market situation

The peptide drug market is growing extremely fast
.

At present, nearly 200 peptide products have been approved worldwide.
In 2016, the global peptide drug market reached 23.
3 billion U.
S.
dollars, accounting for 2% of the pharmaceutical market share
.

In recent years, the global peptide drug market has a compound growth rate of more than 12%, which is higher than the overall drug market.
It is expected to reach 31.
7 billion U.
S.
dollars by 2020.
Among them, there are many large varieties above 1 billion U.
S.
dollars, such as glatiramer and lily.
Laglutide and others
.

       Compared with foreign countries, the market scale of peptide drugs in China is relatively small, but the growth rate is higher than that of the world
.

       Peptide drugs have outstanding advantages
.

       Polypeptide drugs combine the advantages of small molecule drugs and macromolecular protein drugs, and are suitable for the treatment of some complex diseases that are difficult to cure by small molecule drugs.
Polypeptide drugs have high biological activity, strong specificity, and resistance to resistance, etc.
It has become one of the most promising drugs currently
.

       At the same time, the average research and development speed of peptide drugs is faster than other innovative chemical drugs and has high druggability; in terms of amino acid composition, with the maturity of peptide synthesis technology, it is currently possible to synthesize more than 50 amino acid molecules; more and more Polypeptide targets have been applied and developed.
With the deepening of basic research, more and more peptide drug targets or receptors will be discovered
.

       Liu Zhiguo said that as a segment of the pharmaceutical market, peptides have been widely used in the prevention, diagnosis and treatment of diseases such as tumors, hepatitis, diabetes, and AIDS
.

       Difficulties in industrial development

       Although independent innovative peptide original research drugs need to invest enough research and development funds and time, once they are on the market, they can seize the opportunity, have long-term patent protection, and have stronger product competitiveness and long-term value
.

       Peptide raw materials and imitation companies often lack this first-mover advantage and core competitiveness to occupy the market
.

       In addition, the difficulties in the development of the peptide industry are:

• The development cycle of new peptide drugs is long and the investment is large, and many companies do not have enough funds and patience to invest;

• The development of new peptide drugs has high technical barriers, and there is a lack of talents, technology and equipment related to new drug design and screening;

• The key formulation technology is restricted.
  For some special peptide formulations, such as sustained-release microspheres, liposomes, inhalation formulations and other formulations, there are few domestic companies that master the core technology of the above formulations
  .
  

       "Peptide drugs are still facing some challenges, such as synthetic technology, production process and product purity, etc.
, resulting in product quality that does not meet the requirements, or high costs, which limit the development of the peptide industry
.

       Technology breakthrough direction

       In recent years, some multinational companies have performed strongly in the peptide drug market by relying on innovative drug molecules and mechanisms of action, and have maintained a double-digit growth rate
.

       1.
Product innovation perspective

       From the perspective of product innovation, peptide coupling, cell penetrating peptides and new antibacterial peptides are popular research and development directions at home and abroad
.

       Cell penetrating peptides can directly and harmlessly penetrate the cell membrane into the cell, and can mediate and promote the uptake of nanoparticles, small molecules and other substances by the cell; antibacterial peptides can imbalance the cell membrane, thereby achieving the effect of killing bacteria.
It is not easy to make pathogenic bacteria resistant to drugs
.

       2.
Innovative drug delivery methods

       From the perspective of innovations in drug delivery methods, due to the unstable structure of polypeptide molecules in the digestive tract, they can be quickly hydrolyzed, coupled with the liver's first-pass metabolism effect and the possibility of polymer formation, resulting in low oral bioavailability
.

       Stability and other issues can be solved by modifying the modification process.
The biggest obstacle to the development of peptide drugs is that they cannot be administered orally.
The key is to improve the long-term effectiveness of peptide drugs
.

       Generally speaking, a variety of proteolytic enzymes in organisms will rapidly degrade peptide drugs.
Therefore, peptide drugs have poor oral effects and short half-lives
.

       At present, the administration method of peptide drugs is relatively simple, mainly by intravenous injection or drip infusion.
About 75% of peptide drugs are administered by injection
.

       New non-invasive administration methods can improve the safety, compliance and convenience of patients.
For example, cyclic peptide drugs are mostly taken orally or inhaled
.

       With the continuous innovation of peptide drug molecular design technology and peptide drug delivery technology, the key issues that limited the clinical use of peptide drugs in the past (not oral, short half-life, poor cell membrane permeability, etc.
) have been continuously broken
.

       "In addition to solid R&D by pharmaceutical companies, catching up, and gaining access to the international market, the development of peptide drugs requires strong support from national policies.
For example, the inclusion of peptide drugs in the special development strategy of the 14th Five-Year Plan will speed up the development of innovative peptide drugs.
Promoting the development of peptides by national enterprises is a key step for China's new peptide drugs to go global
.

       Expert profile : Liu Zhiguo, founder and director of Zhejiang Paipeptide Bio, began to engage in peptide drug research in 2001, once worked as the project R&D manager of Pfizer Pharmaceuticals, founded Hangzhou Paipeptide R&D Center in 2014, and Zhejiang Paipeptide Biological Co.

       Editor in charge: Houttuynia cordata